Kyverna Therapeutics, Inc.(KYTX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
KYTX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Kyverna Therapeutics, Inc. (KYTX), a Healthcare sector company. KYTX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Kyverna Therapeutics, Inc. reports net income of $-39.7M, free cash flow of $-41.6M. Top institutional holders of KYTX by reported 13-F value include GordonMD Global Investments, GILEAD SCIENCES,, Bain Capital Life Sciences Investors,, based on the most recent SEC filings. KYTX trades on the Nasdaq exchange and files with the SEC under CIK 1994702. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KYTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Kyverna Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-39.7M
Free Cash Flow
Q1 2026
$-41.6M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-26.5% YoYOperating Income
-19.1% YoYEPS (Diluted)
-9.3% YoYTotal Assets
-3.6% YoYOp. Cash Flow
-34.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Net Income | $-161.3M -26.5% | $-127.5M -111.2% | $-60.4M |
| Operating Income | $-169.8M -19.1% | $-142.6M -128.5% | $-62.4M |
| EPS (Diluted) | $-3.64 -9.3% | $-3.33 +96.3% | $-89.61 |
| Total Assets | $293.8M -3.6% | $304.6M +305.1% | $75.2M |
| Operating Cash Flow | $-153.7M -34.5% | $-114.3M -118.0% | $-52.4M |
AI Insight: KYTX Ratio Trends
Kyverna remains deeply unprofitable with worsening returns; ROE deteriorated from -34.5% in Q2 2024 to -81.2% in Q1 2026.
• ROE collapsed 46.7pp over 9 quarters, from -34.5% (Q2 2024) to -81.2% (Q1 2026), signaling severe cash burn and equity destruction.
• ROA worsened from -31.7% (Q2 2024) to -61.8% (Q1 2026), indicating company burns cash on minimal revenue base.
• Q3 2025 hit worst-quarter trough: ROE -96.8%, ROA -78.6%, before partial recovery in Q4 2025.
⚠ TTM ROE -80.0% and ROA -60.9% suggest sustained cash burn; monitor quarterly burn rate and runway to profitability.
⚠ Q4 2025 showed modest recovery (ROE -65.1%) vs. Q3 2025 trough; unclear if sustainable or seasonal blip.
Get alerted when KYTX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Kyverna Therapeutics, Inc. including:
Top Institutional Holders of KYTX
GordonMD Global Investments LP
$36.6M4,244,818 shGILEAD SCIENCES, INC.
$35.6M4,126,119 shBain Capital Life Sciences Investors, LLC
$26.8M3,110,000 shAIGH Capital Management LLC
$17.3M2,000,000 shDEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$17.3M2,000,000 shVANGUARD CAPITAL MANAGEMENT LLC
$15.4M1,783,342 shBALYASNY ASSET MANAGEMENT L.P.
$9.7M1,125,321 shMILLENNIUM MANAGEMENT LLC
$8.7M1,005,508 shInsight Holdings Group, LLC
$8.5M989,054 shMORGAN STANLEY
$8.4M977,289 sh
| Fund | Value | Shares |
|---|---|---|
| GordonMD Global Investments LP | $36.6M | 4,244,818 |
| GILEAD SCIENCES, INC. | $35.6M | 4,126,119 |
| Bain Capital Life Sciences Investors, LLC | $26.8M | 3,110,000 |
| AIGH Capital Management LLC | $17.3M | 2,000,000 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | $17.3M | 2,000,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $15.4M | 1,783,342 |
| BALYASNY ASSET MANAGEMENT L.P. | $9.7M | 1,125,321 |
| MILLENNIUM MANAGEMENT LLC | $8.7M | 1,005,508 |
| Insight Holdings Group, LLC | $8.5M | 989,054 |
| MORGAN STANLEY | $8.4M | 977,289 |
More Healthcare Companies
View all Healthcare →Put KYTX on your watchlist
Track score changes the day Kyverna Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is KYTX a good stock to buy?
13F Pro's AI-powered analysis of Kyverna Therapeutics, Inc. (KYTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KYTX are available on the KYTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own KYTX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KYTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Kyverna Therapeutics, Inc.'s investment landscape.